Staten Island, NY, United States of America

Fa-Xiang Ding

This inventor holds 31 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 24 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Aventis Pharmaceuticals Inc.. Active years: 2009-2025.

USPTO Granted Patents = 31 (Patent Applications = 8)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 24 (Patent Applications = 30)

Average Co-Inventor Count = 7.3

ph-index = 4

Forward Citations = 67(Granted Patents)

Location History:

Kenilworth, NJ (US) (2018)
Staten Island, NJ (US) (2022)
Staten Island, NY (US) (2009 - 2023)

Company Filing History:

29 out of 2,405

Merck Sharp + Dohme Corp.

patents

2 out of 207

Aventis Pharmaceuticals Inc.

patents

Years Active: 2009-2025

Loading Chart...

Areas of Expertise:

Diacylglyceride O-Acyltransferase Inhibitors

PCSK9 Antagonist Compounds

Oxazolidinones

Bicyclic Aryl Monobactam Compounds

Renal Outer Medullary Potassium Channel Inhibitors

Beta-Tetrazolyl-Propionic Acids

Metallo-Beta-Lactamase Inhibitors

Soluble Guanylate Cyclase Activators

Soluble Epoxide Hydrolase Inhibitors

Niacin Receptor Agonists

Casein Kinase I Inhibitors

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12448384 - Diacylglyceride O-acyltransferase 2 inhibitors (2025-10-21),

2. 12209145 - PCSK9 antagonist compounds (2025-01-28),

3. 12178842 - PCSK9 antagonist compounds (2024-12-31),

4. 11738010 - Oxazolidinones as TarO inhibitors (2023-08-29),

5. 11484565 - PCSK9 antagonist compounds (2022-11-01),

6. 11427616 - PCSK9 antagonist compounds (2022-08-30),

7. 11306125 - PCSK9 antagonists bicyclo-compounds (2022-04-19),

8. 11230543 - Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections (2022-01-25),

9. 11141410 - Oxazolidinones as taro inhibitors (2021-10-12),

10. 10947222 - Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 (2021-03-16),

11. 10407421 - Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections (2019-09-10),

12. 10208064 - Inhibitors of the renal outer medullary potassium channel (2019-02-19),

13. 10000484 - Inhibitors of the renal outer medullary potassim channel (2018-06-19),

14. 9926317 - Inhibitors of the renal outer medullary potassium channel (2018-03-27),

15. 9862720 - Inhibitors of the renal outer medullary potassium channel (2018-01-09),

Title: The Inventor Shaping the Future of Pharmaceutical Innovations: Fa-Xiang Ding

Introduction: Fa-Xiang Ding, a prolific inventor based in Staten Island, NY, is making significant strides in the field of pharmaceutical research and development. With an impressive portfolio of 28 patents to his name, Ding is revolutionizing the healthcare industry with his groundbreaking inventions.

Latest Patents:

1. Oxazolidinones as TarO inhibitors: Ding's latest patent introduces novel compounds that inhibit TarO, offering potential in the prevention and treatment of bacterial infections, including MRSA and MRSE.

2. PCSK9 antagonist compounds: Another notable invention by Ding includes compounds that antagonize PCSK9, aiding in the treatment of cardiovascular diseases like atherosclerosis and hypercholesterolemia.

Career Highlights: Ding has contributed his expertise to renowned companies such as Merck Sharp & Dohme Corporation and Aventis Pharmaceuticals Inc., where he played a pivotal role in driving innovation and pushing the boundaries of pharmaceutical research.

Collaborations: Throughout his career, Ding has collaborated with esteemed professionals in the field, including Jinlong Jiang and Shuzhi Dong. Together, they have fostered a culture of innovation and excellence, leading to groundbreaking discoveries in the pharmaceutical industry.

Conclusion: Fa-Xiang Ding's relentless pursuit of innovation and his dedication to advancing healthcare technologies have solidified his reputation as a visionary inventor. His patents and collaborations underscore his commitment to pushing the boundaries of scientific discovery, making him a key figure in the world of pharmaceutical innovations.